Diabetes
Refine Search
Pharmaceutical
In an indecisive vote, The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee yesterday voted eight to eight on the question of whether the overall benefits of Zynquista (sotagliflozin) outweighed the risks to support approval. 18 January 2019
Pharmaceutical
With next to no news releases coming out of government departments due to the virtual government shut down, Health and Human Service Secretary Alex Azar is expressing his frustrations on Twitter regarding continued pressure on drug pricing. 11 January 2019
Biotechnology
Daiichi Sankyo, Mitsubishi UFJ Capital and Tokyo Institute of Technology today announced that they will commence open innovation research with the aim of creating insulin producing cells from iPS cells for use in regenerative medicine and cell therapy. 10 January 2019
Biotechnology
Merck & Co today revealed it has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes 4 January 2019
Biosimilars
The US Patent and Trademark Appeal Board (PTAB) has ruled in favor of Netherlands-based drugmaker Mylan as it invalidated Sanofi’s Lantus (insulin glargine 100 Units/mL) formulation patents. 14 December 2018
Pharmaceutical
The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the USA. 13 December 2018
Pharmaceutical
Danish diabetes company Novo Nordisk has signed a research collaboration with e-therapeutics, a UK-based company with a computer-based drug discovery platform. 10 December 2018
Pharmaceutical
A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. 27 November 2018
Pharmaceutical
Among featured M&A news last week, US devices company Boston Scientific made a $4.24 billion bid for UK-based specialty pharma firm BTG, and there was also talk that US immuno-oncology company Tesaro may be putting itself up for sale. On the research front, there was disappointment for Germany’s Merck KGaA and US partner Pfizer as their immune checkpoint inhibitor Bavencio (avelumab) failed to meet endpoints in a Phase III ovarian cancer study. But there was better news for Danish diabetes care giant Novo Nordisk, with positive cardiovascular outcomes with its oral semaglutide in the PIONEER 9 trial. 25 November 2018
Pharmaceutical
Novo Nordisk got a boost on Friday with the latest findings from a series of studies with its oral form of the diabetes drug semaglutide, sending the firm’s shares up 3.66% to 297.00 Danish kroner by close of trading. 24 November 2018
Pharmaceutical
Geropharm, one of Russia’s leading drugmakers, has officially commissioned a new plant for the production of insulin substances in St Petersburg, according to the company. 22 November 2018
Biotechnology
Novo Nordisk’s (NOV: N) decision to spend up to $800 million buying the synthetic glucose specialist Ziylo has thrown a spotlight on Unit DX, a biotech incubator based in Bristol, UK. 15 November 2018
Pharmaceutical
Research from industry analyst GlobalData highlights progress in developing new therapies for diabetes, while identifying significant areas of unmet need. 14 November 2018
Biotechnology
Shares in Anglo-Swedish pharma major AstraZeneca were nearly 7% higher than they were a week ago on Monday lunchtime as data on Farxiga (dapagliflozin) bumped up the company’s stock further. 12 November 2018
Pharmaceutical
AstraZeneca’s enormous investment in R&D in the last five years means that pipeline updates are seen as more important than quarterly results – a fact that was again evident on Thursday. 8 November 2018
Pharmaceutical
Eli Lilly gave investors reasons for optimism in presenting its third-quarter financial results. 6 November 2018
Pharmaceutical
Proving that diabetes drugs can reduce cardiovascular (CV) events is seen as vital by drugmakers in the space, and US pharma major Eli Lilly has responded to progress made by other treatments in this area by presenting data on Trulicity (dulaglutide). 6 November 2018
Pharmaceutical
Novartis has invested over $150 million in the development of its Russian plant in St Petersburg, and is considering further investments in the near future, according to recent statements by Vadim Vlasov, president of the Swiss pharma giant’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 5 November 2018
Pharmaceutical
Boehringer Ingelheim and Eli Lilly have released positive initial results from the real-world EMPRISE study examining cardiovascular outcomes related to Jardiance (empagliflozin). 5 November 2018
Pharmaceutical
Since the 1980s, China's economic development has improved living standards and urbanization level, which significantly increases the incidence of obesity, diabetes and other non-communicable diseases in China. 2 November 2018
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze